EBOS Group (EBO) H2 2026 earnings summary

Executive summary

• Revenue increased 9.9% to AUD 13.5 billion and underlying EBITDA rose 5% to AUD 614 million for FY26, both within guidance, supported by broad-based growth and recent acquisitions.

• Completion of a AUD 360 million multi-year distribution center renewal program, with all facilities now operational, shifting focus from investment to productivity and future growth.

• Strategic acquisitions, including Paringa Pet Foods and K-Talyst, expanded capabilities in premium pet food, aesthetics, and higher-growth markets.

• 85% of EBITDA now comes from businesses ranked first or second in their sectors, with a strategic shift toward higher growth, higher return segments.

• Entering FY27 with a stronger portfolio, lower capital intensity, and capacity for future growth investments.

Financial highlights

• Underlying NPAT reached AUD 250 million (down 3.1% year-over-year); statutory EBITDA up 7.8% and NPAT up 4.7%.

• Underlying EPS was 121.7c (down 7.3%), with statutory EPS at 109.8c (up 0.1%).

• EBITDA margin ended slightly down at 4.6% due to product mix and competitive dynamics in Community Pharmacy.

• Free cash flow was AUD 204 million, with net working capital well controlled and cash conversion days stable at 20.

• Final dividend maintained at NZ 61.5 cents per share, payout ratio 84.5% of underlying NPAT.

Outlook and guidance

• FY27 guidance targets mid-single-digit organic EBITDA growth (AUD 635–655 million), with no new acquisitions assumed.

• CapEx expected to normalize at AUD 100 million, supporting stronger free cash flow and improved returns.

• Focus on productivity, utilization, leveraging new capacity, and expanding medical technology and animal care.

• Guidance incorporates potential FX and fuel cost scenarios, with mitigation strategies in place.

• ~$150 million capital available for further bolt-on M&A.